Phase 2 study of famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory TNBC

Camrelizumab, a monoclonal antibody against PD-1, plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. The phase 2 FUTURE-C-PLUS trial at Fudan University (Shanghai, China) evaluated the combination of famitinib, camrelizumab and nab-paclitaxel for previously untreated, advanced, immunomodulatory TNBC. The triplet regimen was well tolerated and efficacious, with ORR 81.3%, median PFS 13.6 months, median DOR 14.9 months, and median OS not reached.